中性粒细胞明胶酶相关脂质运载蛋白用于评估肝硬化急性肾损伤:一项前瞻性研究
这项前瞻性研究纳入320例因失代偿期肝硬化住院的急性肾损伤(AKI)患者,评估尿液中性粒细胞明胶酶相关脂质运载蛋白(NGAL)等生物标志物在鉴别急性肾小管坏死(ATN)与其它类型AKI及预测预后中的准确性。第3天尿NGAL鉴别ATN的曲线下面积(AUC)为0.87(95%CI 0.78-0.95),最佳阈值为220 µg/g肌酐。NGAL是AKI进展和28天死亡率的独立预测因素,结果支持在诊断流程中使用NGAL。
要点
- 第3天尿NGAL鉴别ATN与其它AKI类型的AUC为0.87(95%CI 0.78-0.95)。
- 诊断ATN的最佳NGAL阈值为220 µg/g肌酐。
- NGAL是AKI进展和28天死亡率的独立预测因素。
核心结论
- 结果支持在诊断流程中应用NGAL用于肝硬化AKI的鉴别诊断和结局预测。
研究设计与样本
- 前瞻性研究,纳入320例因失代偿期肝硬化住院的连续AKI病例。
- AKI评估采用诊断流程,包括识别和去除/治疗诱因,并对AKI 1B期及以上患者给予白蛋白(1 g/kg,2天)。
- 在诊断时及第3、7、14天检测尿NGAL、单体NGAL(mNGAL)、白细胞介素-18及标准生物标志物。
主要发现
- 320例中,低血容量诱发性AKI 153例(48%),HRS-AKI 93例(29%),ATN 39例(12%),其它原因35例(11%)。
- 第3天尿NGAL鉴别ATN与其它AKI类型的AUC为0.87(95%CI 0.78-0.95),在所有生物标志物中准确性最高。
- 诊断ATN预测准确性最佳的阈值为220 µg/g肌酐。
- 住院期间AKI进展与持续高NGAL水平相关,NGAL是AKI进展的独立预测因素。
- NGAL与MELD评分一起也是28天死亡率的独立预测因素。
关键数值与推荐
- 第3天尿NGAL鉴别ATN的AUC为0.87(95%CI 0.78-0.95)。
- 诊断ATN的最佳预测阈值为220 µg/g肌酐。
- AKI 1B期及以上患者给予白蛋白1 g/kg,2天。
临床怎么用
- 作者认为结果支持在临床实践中将NGAL纳入肝硬化AKI的诊断流程,用于鉴别诊断和结局预测。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Kidney biomarkers appear to be useful in differential diagnosis between acute tubular necrosis (ATN) and other types of acute kidney injury (AKI) in cirrhosis, particularly hepatorenal syndrome (HRS-AKI). Distinction is important because treatment is different. However, kidney biomarkers are still not used in clinical practice. The aim of the current study was to investigate the accuracy of several biomarkers in differential diagnosis of AKI and in predicting kidney outcome and patient survival. This was a prospective study of 320 consecutive cases of AKI in patients hospitalized for decompensated cirrhosis. Evaluation of AKI was made with a diagnostic algorithm that included identification and removal/treatment of precipitating factors and albumin administration (1 g/kg for 2 days) to patients with AKI stage 1B or greater. Urinary neutrophil gelatinase-associated lipocalin (NGAL), monomeric NGAL (mNGAL), interleukin-18, and standard biomarkers were measured at diagnosis and on days 3, 7, and 14. Of the 320 cases, 153 were hypovolemia-induced AKI (48%), 93 were HRS-AKI (29%), 39 were ATN (12%), and 35 were due to miscellaneous causes (11%). Among all biomarkers, urinary NGAL measured at day 3 had the greatest accuracy for differential diagnosis between ATN and other types of AKI (area under the receiver operating characteristic curve, 0.87; 95% confidence interval, 0.78-0.95). The cutoff with the best predictive accuracy for ATN diagnosis was 220 µg/g creatinine. Progression of AKI during hospitalization was associated with persistently high NGAL levels, and NGAL was an independent predictive factor of AKI progression. Likewise, NGAL was also an independent predictive factor of 28-day mortality together with Model for End-Stage Liver Disease score. Conclusion: These results support the use of NGAL in clinical practice within the context of a diagnostic algorithm for differential diagnosis of AKI and outcome prediction in cirrhosis.
引用
- Huelin P, Solà E, Elia C, et al. Neutrophil Gelatinase-Associated Lipocalin for Assessment of Acute Kidney Injury in Cirrhosis: A Prospective Study. Hepatology. 2019. PMID: 30810244. doi:10.1002/hep.30592
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。